News in brief: Synergy with bone resorption inhibitors + abiraterone in mCAPC; ICIs benefit some advanced MPeM patients; Australia wins bronze in global health services ranking

Synergy with bone resorption inhibitors and abiraterone in mCAPC The addition of bone resorption inhibitors (BRIs) to abiraterone acetate with prednisone as first line therapy for metastatic castration-resistant prostate cancer (mCRPC) with bone metastases improves overall survival. According to a retrospective cohort study of 745 men published in JAMA Network Open, BRIs improved OS (31.8 ...

Already a member?

Login to keep reading.

© 2022 the limbic